CAMBRIDGE, Mass., May 18, 2022
/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX)
(Theseus or the Company), a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients through
the discovery, development and commercialization of transformative
targeted therapies, today announced the appointment of Don Hayden to its Board of Directors.
"We are thrilled to welcome Don as a tremendous addition to the
Theseus Board. Don is a recognized, deeply experienced leader in
the industry, and he will bring a unique perspective to Theseus as
we advance our Phase 1/2 clinical trial of THE-630 in patients with
GIST and expect to file an IND for our second program in
EGFR-driven non-small cell lung cancer in 2023," said Tim Clackson, Ph.D., President and Chief
Executive Officer of Theseus. "Don is an industry veteran with a
record of success as an executive at large pharmaceutical
companies, as well as board and board chair experience at multiple
biopharmaceutical companies. We are sure to benefit from his
knowledge and insights as we accelerate our clinical
portfolio."
Mr. Hayden has over 40 years of experience in the life sciences
industry, having served in numerous strategic leadership positions
during his 25-year career at Bristol Myers-Squibb Company (BMS),
including roles as President of Oncology and Immunology and as
President of Global Pharmaceuticals. Following BMS, Mr. Hayden has
served as Chair at REGENXBIO, Amicus Therapeutics, Insmed, Vitae
Pharmaceuticals, and Gloucester Pharmaceuticals, among others,
across which he provided strategic guidance through a variety of
corporate milestones, including business combinations, financings,
IPOs, and bringing approved therapies to market. More recently, Mr.
Hayden served as Chair and CEO of oncology cell therapy developer,
WindMIL Therapeutics. In addition to his new role at Theseus, Mr.
Hayden also currently serves as Chair of Otsuka America
Pharmaceuticals Incorporated. He holds an M.B.A from Indiana University and undergraduate degree from
Harvard University.
Mr. Hayden added, "Theseus has an exceptional leadership team,
with substantial success in targeted oncology, and shows immense
potential to combat cancer treatment resistance with its
pan-variant approach to targeted therapy. I look forward to
supporting the Company's continued growth and clinical development,
as it seeks to translate the power of its unique science into
significant benefits for cancer patients."
About Theseus Pharmaceuticals, Inc.
Theseus is a
clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients through the discovery, development and
commercialization of transformative targeted therapies. Theseus is
working to outsmart cancer resistance by developing pan-variant
tyrosine kinase inhibitors (TKIs) to target all known classes of
cancer-causing and resistance mutations that lead to variants in a
particular protein in a given type of cancer. Theseus' lead product
candidate, THE-630, is a pan-variant KIT inhibitor for the
treatment of patients with advanced gastrointestinal stromal tumors
(GIST), whose cancer has developed resistance to earlier lines of
kinase inhibitor therapy. Theseus is also developing a
fourth-generation, selective epidermal growth factor receptor
(EGFR) inhibitor for C797S-mediated resistance to first- or
later-line osimertinib treatment in patients with non-small cell
lung cancer (NSCLC). For more information, visit
www.theseusrx.com.
Cautionary Statement Regarding Forward Looking
Statements
Certain statements included in this press release
are not historical facts but are forward-looking statements for
purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as "believe,"
"may," "will," "estimate," "continue," "anticipate," "intend,"
"expect," "should," "would," "plan," "on track," "predict,"
"potential," "seem," "seek," "future," "outlook," and similar
expressions that predict or indicate future events or trends or
that are not statements of historical matters, but the absence of
these words does not mean that a statement is not forward-looking.
These forward-looking statements include, but are not limited to,
statements regarding Theseus' strategy, future operations,
prospects and plans, the structure and timing of its preclinical
studies and clinical trials, expected milestones, market
opportunity and sizing and objectives of management, including in
relation to the Phase 1/2 dose escalation and expansion clinical
trial for THE-630, EGFR inhibitor program and other programs and
development candidates.
Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, such as those described from time to time in the reports
Theseus files with the Securities and Exchange Commission (SEC),
including Theseus' Form 10-K for the year ended December 31, 2021 filed with the SEC on
March 10, 2022 and Theseus' Form 10-Q
for the quarter ended March 31, 2022
filed with the SEC on May 12, 2022.
However, new risk factors and uncertainties may emerge from time to
time, and it is not possible to predict all risk factors and
uncertainties. Accordingly, readers are cautioned not to place
undue reliance on these forward-looking statements. Any
forward-looking statements contained in this press release are
based on the current expectations of Theseus' management team and
speak only as of the date hereof, and Theseus specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except as required by law.
Media Contact
Amy Jobe,
Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contact
Christen
Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-appoints-don-hayden-to-board-of-directors-301549652.html
SOURCE Theseus Pharmaceuticals